Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanism-based reasoning without systematic methodology or primary human trial data
What was done
This narrative review synthesizes the pharmacokinetic and pharmacodynamic mechanisms driving motor response fluctuations in Parkinson's disease and evaluates strategies to stabilize brain dopaminergic activity.
What was found
The abstract reports no primary quantitative data or effect sizes. It describes how rapid systemic clearance of levodopa produces short-duration clinical responses as central dopamine storage capacity deteriorates, leading to oscillations in brain dopamine levels and subsequent dyskinesias. Potential stabilizing approaches discussed include controlled-release levodopa, long-acting dopamine agonists, and dopamine extenders such as deprenyl.
Why it matters
It articulates the pharmacological rationale for continuous dopaminergic delivery strategies to mitigate or prevent disabling motor fluctuations in advanced Parkinson's disease.
Limits
The paper is a non-systematic narrative review lacking empirical trial data, explicit study selection criteria, sample sizes, or quantitative outcome measures.
Cited by
- supports In Parkinson's disease progression, surviving dopaminergic neurons lose the capacity to properly store dopamine, contributing to the need for more frequent levodopa dosing.